|Standard Curve Range||7.18 pg/mL-1000 pg/mL|
|Assay Time||2 hr|
|Suitable Sample Type||For the quantitative determination of human IFN-γ in Plasma and Serum.|
|Sample volume||50 μL|
|CEA006-C01||Pre-coated Anti-IFN-γ Antibody Microplate||1 plate|
|CEA006-C02||IFN-γ Calibrator||15 μg×2|
|CEA006-C03||Biotin-Anti-IFN-γ Antibody Concentrated Solution||100 μL|
|CEA006-C04||Biotin Antibody Dilution Buffer||8 mL|
|CEA006-C05||IFN-γ Streptavidin-HRP Concentrated Solution||0.5 mL|
|CEA006-C06||Streptavidin-HRP Dilution Buffer||15 mL|
|CEA006-C07||20× Washing Buffer||50 mL|
|CEA006-C08||Sample Dilution Buffer||15 mL×2|
|CEA006-C09||Substrate Solution||12 mL|
|CEA006-C10||Stop Solution||6 mL|
A comprehensive validation of the ELISA method was performed following the ICH M10 on bioanalytical method validation and the FDA’s bioanalytical method validation guidance for industry. This validation included assessments of linearity, accuracy, precision, dilution linearity, recovery, and the hook effect. For details information, please refer to the DS.
ClinMax™ ELISA Kits are manufactured in a GMP-certified facility and comply to the ISO 13485 standard, ensuring a high level of quality and reliability.
Results are obtained by Log-Log Linear regression equation are used to draw the standard curve and calculate the sample concentration. The verification results indicate that this kit can be used for the quantitative determination of natural and recombinant human IFN-γ concentrations.
It has been calibrated against a highly purified human IFN-γ and is evaluated with standard from NIBSC/WHO. Reference Reagent INTERFERON GAMMA (Human, rDNA derived) NIBSC code: 87/586.
It is for research use only.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
For each experiment, each ELISA plate needs to set the standard curve. The minimum detectable concentration of CEA-C006 is less than 4.0 pg/mL.
Three human serum samples with high concentrations of IFN-γ were diluted 1:2, 1:4, 1:8, 1:16, 1:32, 1:64 with Dilution Buffer to produce samples with values within the dynamic range and then assayed. On average, 99.58% of IFN-γ was detected from serum samples.
Ten replicates of each of five samples containing different IFN-γ concentrations were tested in one assay, Intra-Assay Precision CV<10%.
Five samples containing different concentrations of IFN-γ were tested in three independent assays, Inter-Assay Precision CV<15%.
Recombinant IFN-γ（8000，6000，4000pg/mL）was spiked into 5 human serum samples, and then analyzed. On average, 98.28% of IFN-γ was recovered from serum samples.
Bilirubin (simulated jaundice) concentration should be less than 20mg/dL, hemoglobin (simulated hemolysis) concentration should not be higher than 3500mg/dL, triglyceride (simulated lipemia) concentration may not be higher than 2.0g/L，EDTA concentration should be less than 4mg/mL, and Sodium citrate concentration may not be higher than 40mg/mL，it does not affect the detection result.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(EUR) : €550.00
ACROBiosystems offers a wide selection of Matrigengel basement membrane extracts. Different versions – including phenol red-free, high concentration, iPSC culturing, organoid culturing – are all available for your specific needs to support 3D cell culture!
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
|English Name||Research Code||Research Phase||Company||First Brand Name||First Approved Country||First Indication||First Approved Company||First Approved Fecha||Indications||Clinical Trials|
|Thalidomide||NSC-66847; NSC-527179; K-17; VP-02||Approved||Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled||Mainland China||Leprosy, Lepromatous||Fujimoto Pharmaceutical||1982-01-01||Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma;||Details|
|Cadi-05||Cadi-05||Approved||National Institute Of Allergy And Infectious Diseases (Niaid)||Immuvac, Leprovac, Mycidac-C||India||Carcinoma, Non-Small-Cell Lung; Leprosy||null||1998-01-01||Leprosy; Carcinoma, Non-Small-Cell Lung||Details|
|Emapalumab||NI-0501||Approved||Novimmune Sa||Gamifant||United States||Lymphohistiocytosis, Hemophagocytic||Novimmune Sa||2018-11-20||Still's Disease, Adult-Onset; Macrophage Activation Syndrome; Rare Diseases; Arthritis, Juvenile; Immune System Diseases; Lupus Erythematosus, Systemic; Lymphohistiocytosis, Hemophagocytic||Details|
|English Name||Research Code||Research Phase||Company||Indications||Clinical Trials|
|IFN-gamma-secreting HAdV antigen specific T cells (Case Comprehensive Cancer Center)||Case Comprehensive Cancer Center||Details|
|SP-002||SP-002; ASN-002; TG-1042||Phase 2 Clinical||Transgene Sa||Solid tumours; Lymphoma, B-Cell; Carcinoma, Basal Cell; Skin Neoplasms; Basal Cell Nevus Syndrome; Melanoma||Details|
|OCH-NCNP1||OCH-NCNP1||Phase 2 Clinical||Keio University||Multiple Sclerosis; Crohn Disease||Details|
|Tadekinig alfa (AB2 Bio)||Phase 3 Clinical||Ab2 Bio Ltd||Macrophage Activation Syndrome; Cytokine Release Syndrome; Lymphohistiocytosis, Hemophagocytic||Details|
|YH-32367||ABL105; YH-32367||Phase 2 Clinical||Abl Bio Inc||Solid tumours; Stomach Neoplasms; Breast Neoplasms||Details|
|EI-001||EI-001||Phase 1 Clinical||Elixiron Immunotherapeutics Inc||Vitiligo||Details|
|KIO-100||PP-001; KIO-101; KIO-100||Phase 2 Clinical||4sc Ag||Dry Eye Syndromes; Uveitis; Xerophthalmia; Keratoconjunctivitis||Details|
|PDS-0101||PDS-0101B; PDS-0101C; PDS-0101; PDS-0101A; PDS-101||Phase 2 Clinical||Pds Biotechnology Corporation, Merck Serono||Head and Neck Neoplasms; Anus Neoplasms; Papillomavirus Infections; Vulvar Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Uterine Cervical Neoplasms||Details|
|Recombinant human interferon gamma adenovirus injection (Guangzhou Dabo Biological Products)||Phase 1 Clinical||Guangzhou Dabo Biological Products Co Ltd||Liver Neoplasms; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant||Details|
This web search service is supported by Google Inc.